Menu
Search
|

Menu

Close
X

Innoviva Inc INVA.OQ (NASDAQ Stock Exchange Global Select Market)

16.74 USD
-0.06 (-0.36%)
As of Feb 17
chart
Previous Close 16.80
Open 16.75
Volume 318,043
3m Avg Volume 268,721
Today’s High 16.98
Today’s Low 16.65
52 Week High 17.21
52 Week Low 11.06
Shares Outstanding (mil) 109.36
Market Capitalization (mil) 1,566.05
Forward P/E 20.00
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
3.25 Mean rating from 4 analysts

KEY STATS

Revenue (mm, USD)
FY17
217
FY16
134
FY15
54
EPS (USD)
FY17
1.120
FY16
0.441
FY15
-0.163
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
20.00
32.90
Price to Sales (TTM)
vs sector
8.90
5.77
Price to Book (MRQ)
vs sector
--
5.41
Price to Cash Flow (TTM)
vs sector
14.71
23.42
Total Debt to Equity (MRQ)
vs sector
--
16.52
LT Debt to Equity (MRQ)
vs sector
--
12.22
Return on Investment (TTM)
vs sector
26.11
14.43
Return on Equity (TTM)
vs sector
--
16.13

EXECUTIVE LEADERSHIP

William Waltrip
Independent Chairman of the Board, Since 2014
Salary: --
Bonus: --
Eric D'Esparbes
Interim Principal Executive Officer, Chief Financial Officer, Senior Vice President, Since 2018
Salary: $383,840.00
Bonus: $182,585.00
Theodore Witek
Senior Vice President, Chief Scientific Officer, Since 2015
Salary: $407,105.00
Bonus: $193,857.00
George Bickerstaff
Independent Director, Since 2017
Salary: --
Bonus: --
Barbara Duncan
Independent Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Pharmaceuticals
Address:

2000 Sierra Point Pkwy Ste 500
BRISBANE   CA   94005-1830

Phone: +1650.2389600

Innoviva, Inc., formerly Theravance, Inc., is engaged in the development, commercialization and financial management of bio-pharmaceuticals. It focuses on the respiratory assets partnered with Glaxo Group Limited (GSK), including RELVAR/BREO ELLIPTA (fluticasone furoate (FF)/vilanterol (VI)) and ANORO ELLIPTA (umeclidinium bromide/vilanterol (UMEC/VI)). Under the Long-Acting Beta2 Agonist (LABA) Collaboration Agreement and the Strategic Alliance Agreement with GSK, the Company is eligible to receive the annual royalties from GSK on sales of RELVAR/BREO ELLIPTA. For other products combined with a LABA from the LABA collaboration, such as ANORO ELLIPTA, royalties are upward tiering and range from 6.5% to 10%. RELVAR/BREO is a once-a-day combination inhaled respiratory medicine consisting of a LABA (VI) and an inhaled corticosteroid (ICS), FF. ANORO ELLIPTA a once-daily medicine combining a long-acting muscarinic antagonist (LAMA), umeclidinium bromide (UMEC), with a LABA.

SPONSORED STORIES